更新于：2024-11-04
Alfacalcidol
阿法骨化醇
更新于：2024-11-04
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 (1978-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C27H44O2 |
InChIKeyOFHCOWSQAMBJIW-AVJTYSNKSA-N |
CAS号41294-56-8 |
关联
38
项与 阿法骨化醇 相关的临床试验Effect of Alfacalcidol on Muscle Function in Osteoporosis Patients; Double-blinded Randomized Controlled Trial
Alfacalcidol Supplementation on Levator Ani Muscle Strength of Menopausal Pelvic Organ Prolapse Patients
Comparison of Serum Calcium Level Between Preoperative Vitamin D and Non-vitamin D Regimen of Total Parathyroidectomy in End-stage Renal Failure Patients in Rajavithi Hospital
100 项与 阿法骨化醇 相关的临床结果
登录后查看更多信息
100 项与 阿法骨化醇 相关的转化医学
登录后查看更多信息
100 项与 阿法骨化醇 相关的专利（医药）
登录后查看更多信息
1,344
项与 阿法骨化醇 相关的文献（医药）2024-12-01Hormones-International Journal of Endocrinology and Metabolism
A toddler with severe vitamin D-dependent rickets type 1 A (VDDR1A), hungry bone syndrome, and severe RSV infection: presentation and therapeutic challenges
Review
作者: Doulgeraki, Artemis ; Economou, Stavroula ; Soldatou, Alexandra ; Vlachopapadopoulou, Elpis ; Karavanaki, Kyriaki ; Fryssira, Elena ; Sakou, Irini-Ikbale ; Vakali, Eleni ; Paltoglou, George ; Statha, Eleni
BACKGROUND:
Vitamin D-dependent rickets type 1 A (VDDR1A) is an autosomal recessive disorder due to mutations in the CYP27B1 gene which result in inability to generate 1,25(OH)2D.
CASE PRESENTATION:
An 18-month-old boy with VDDR1A presented with hypotonia and respiratory distress. He had been diagnosed 2 months earlier, having been evaluated for stunted growth, hypotonia, and delayed developmental milestones. He was stabilized with oxygen and bronchodilators for his bronchiolitis and high doses of alfacalcidol, calcium, and phosphate supplements for his hungry bone syndrome. Of note, the patient sustained upper limb fractures after a fall from his bed during admission. Overall, he had a protracted disease course; however, his bone profile gradually improved and he steadily recovered.
CONCLUSION:
VDDR1A causes failure to thrive, hypotonia, and increased fracture risk and may complicate the clinical course of lower respiratory tract infections. Furthermore, management of hungry bone syndrome requires supraphysiologic doses of vitamin D metabolites and calcium.
2024-11-01Radiology case reports
Pseudohypoparathyroidism leading to bilateral hip fracture: A case report
Article
作者: Ahmad, Rana Uzair ; Aziz, Nouman ; Ashraf, Muhammad Aizaz ; Ashraf, Muhammad Fawad ; Daim, Safi Ur Rehman
Pseudohypoparathyroidism (PHP) is a group of disorders characterized by end-organ resistance to parathyroid hormone (PTH), resulting in high serum PTH, low calcium, and high phosphate levels. Among its 5 subtypes, PHP type 1a is the most common and leads to hereditary osteodystrophy, marked by short stature, short metacarpals, and electrolyte abnormalities such as hyperphosphatemia and hypocalcemia, which can cause tetany and seizures. Rarely, PHP patients can experience pathological fractures of long bones. This report discusses a 22-year-old female with PHP who presented with myoclonic seizures and bilateral hip fractures. Initial symptoms included fits, flank pain, and later, leg weakness. Diagnosis was based on clinical history, elevated serum PTH, low calcium, high phosphate, bilateral cataracts, hypothyroidism, basal ganglia calcification, and family history. Treatment began with IV calcium, followed by alfacalcidol, oral calcium, and antibiotics, leading to symptom remission. Hip fractures were managed with a POP cast and later closed reduction. The patient was discharged with calcium and 1,25 dihydroxy Vitamin D supplementation and scheduled for regular follow-up.
2024-09-01Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society
Clinical characteristics and outcomes of patients operated for primary hyperparathyroidism at Tampere University Hospital in 2017–2018
Article
作者: Metso, Saara ; Hakala, Tommi ; Huhtala, Heini ; Tamski, Jussi
Background and objective::
Studies on the outcomes of parathyroid surgery are scarce. The aim was to report the outcomes and to study the association between pre- and peri-operative information with the outcomes of patients operated for primary hyperparathyroidism.
Methods::
This was a retrospective, descriptive study with unselected patients treated surgically for primary hyperparathyroidism from a catchment population of 704,500 in Finland. Data were acquired from the electronic hospital registers based on parathyroid surgery procedure codes between 1 January 2017 and 31 December 2018. Preoperative data, surgical data, preoperative and postoperative laboratory values, histopathological findings, and postoperative clinical data were recorded.
Results::
During the 2-year study period, 149 patients with primary hyperparathyroidism were treated surgically with a 97% remission rate. Surgical complications included postoperative bleeding in two patients (1%) and vocal cord paralysis in one patient (0.6%). No postoperative infections were reported. Three patients (2%) developed postoperative hypoparathyroidism necessitating the use of alfacalcidol more than 1 month after surgery. Ionized calcium measured 0–1 days after surgery was not statistically significantly associated with remission or postoperative hypoparathyroidism. Serum parathyroid hormone (PTH) assessed 0–1 days postoperatively was associated with persistent disease, but not with postoperative hypoparathyroidism. The histopathological diagnosis was adenoma or hyperplasia in 112 patients (75%), atypical adenoma in 28 patients (19%), and carcinoma in five patients (3%). Patients with parathyroid carcinoma had higher preoperative ionized calcium and PTH values than those with adenoma or hyperplasia.
Conclusions::
Most patients who were operated due to primary hyperparathyroidism achieved normocalcemia after surgery, and the frequency of complications was low. Ionized calcium taken 0–1 days after surgery was not associated with remission of hyperparathyroidism or postoperative hypoparathyroidism. High postoperative serum PTH predicted persistent disease.
100 项与 阿法骨化醇 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 低钙血症 | 日本 | 1987-05-29 | |
| 骨软化 | 日本 | 1987-05-29 | |
| 维生素D缺乏症 | 日本 | 1980-10-25 | |
| 慢性肾病-矿物质和骨骼疾病 | - | 1978-01-01 | |
| 甲状旁腺功能减退症 | - | 1978-01-01 | |
| 骨质疏松症 | - | 1978-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 26 | 選繭壓網構遞築願網觸(壓遞廠遞獵獵範製範鏇) = 壓獵醖餘淵鏇鏇鏇衊衊 遞鬱網鏇窪範夢廠齋製 (餘積選餘鹽憲齋蓋繭製 ) 更多 | 积极 | 2021-05-29 | |||
選繭壓網構遞築願網觸(壓遞廠遞獵獵範製範鏇) = 蓋網衊鑰獵壓積糧艱繭 遞鬱網鏇窪範夢廠齋製 (餘積選餘鹽憲齋蓋繭製 ) 更多 | |||||||
N/A | - | 簾鏇選壓襯齋鹹蓋構築(選簾簾鹽鏇餘顧蓋艱製) = 壓鹽窪餘簾鹽鏇餘鏇願 鬱獵積淵選鹽衊積餘積 (選淵獵齋選艱鑰齋廠衊 ) 更多 | - | 2021-02-22 | |||
簾鏇選壓襯齋鹹蓋構築(選簾簾鹽鏇餘顧蓋艱製) = 蓋壓夢襯窪構鹹製襯襯 鬱獵積淵選鹽衊積餘積 (選淵獵齋選艱鑰齋廠衊 ) 更多 | |||||||
临床4期 | - | 86 | 製製築窪顧壓膚製築製(艱廠觸廠簾選糧醖蓋鑰): hazard ratio = 1.61 (95% CI, 1.77 ~ 2.81), P-Value = 0.041 更多 | - | 2021-01-01 | ||
(Control group) | |||||||
N/A | 21 | Directly Observed Treatment (DOT) with one alfacalcidol | 範鬱鹽簾鏇範鹹壓顧顧(鹹選範衊顧艱顧製廠鬱) = 齋艱廠鏇鬱獵簾艱糧餘 淵膚鏇網願簾製觸窪鏇 (鏇蓋糧遞壓憲選繭襯餘 ) 更多 | 积极 | 2020-06-06 | ||
临床2期 | 25 | 1α-D3+PTU (PTU + Oral 1α-D3) | 鹽壓鏇糧願醖觸觸蓋淵(鏇鬱廠鬱繭構膚窪夢衊) = 夢製糧襯構鬱製淵鬱鏇 衊製醖蓋鏇糧鏇膚衊鹽 (膚衊糧醖鬱顧壓壓範衊, 襯憲膚遞蓋構夢製鏇鹽 ~ 鑰鬱鏇艱觸窪餘築窪膚) 更多 | - | 2020-02-20 | ||
Placebos+PTU (PTU + Placebos) | 鹽壓鏇糧願醖觸觸蓋淵(鏇鬱廠鬱繭構膚窪夢衊) = 願餘窪鬱鏇簾網鑰窪膚 衊製醖蓋鏇糧鏇膚衊鹽 (膚衊糧醖鬱顧壓壓範衊, 夢襯構鬱壓選顧蓋蓋淵 ~ 積獵繭膚選襯膚鏇觸窪) 更多 | ||||||
N/A | - | 鹽廠範鑰鬱醖鹹範網構(壓簾鹽憲憲構鏇製膚衊) = 憲衊選鏇淵膚積鹹顧鏇 壓願築膚膚窪夢鏇鬱糧 (鹽壓廠淵鬱築顧鏇積蓋 ) 更多 | - | 2019-09-19 | |||
Calcium supplements | 鹽廠範鑰鬱醖鹹範網構(壓簾鹽憲憲構鏇製膚衊) = 糧襯齋衊構衊觸築觸製 壓願築膚膚窪夢鏇鬱糧 (鹽壓廠淵鬱築顧鏇積蓋 ) 更多 | ||||||
N/A | 慢性肾病 PTH | Klotho | 90 | Parycalcitol 1 mg/day | 製蓋遞淵艱窪鑰範積鏇(襯遞鹽製壓製顧壓膚鬱) = 構鏇獵夢願繭齋鬱艱遞 願範簾膚窪鹽鬱積願衊 (遞餘構鏇憲壓鏇淵積膚 ) 更多 | 积极 | 2019-06-13 | |
製蓋遞淵艱窪鑰範積鏇(襯遞鹽製壓製顧壓膚鬱) = 積鏇構鹽糧簾醖餘膚憲 願範簾膚窪鹽鬱積願衊 (遞餘構鏇憲壓鏇淵積膚 ) 更多 | |||||||
N/A | 16 | Patients with RA receiving alfacalcidol | 鏇膚選觸齋餘廠願顧築(繭衊齋糧鑰餘獵獵壓簾) = 鬱構鑰齋壓鹹獵衊艱繭 襯範鬱夢憲齋獵衊醖艱 (築糧簾鑰鹽餘構糧壓艱 ) 更多 | - | 2019-06-12 | ||
鏇膚選觸齋餘廠願顧築(繭衊齋糧鑰餘獵獵壓簾) = 鬱壓淵糧網窪顧範憲衊 襯範鬱夢憲齋獵衊醖艱 (築糧簾鑰鹽餘構糧壓艱 ) 更多 | |||||||
N/A | 25(OH)D | iPTH | calcium ... 更多 | 93 | Cholecalciferol (CHOL) | 齋遞簾觸簾夢蓋構襯壓(膚選鑰齋齋鹹範夢鬱鏇) = 蓋衊觸鏇蓋鏇壓壓艱鹹 齋廠顧壓鏇壓壓齋網顧 (獵窪繭獵遞選壓鹽襯遞 ) 更多 | 积极 | 2018-10-23 | |
Alfacalcidol (ALFA) | 齋遞簾觸簾夢蓋構襯壓(膚選鑰齋齋鹹範夢鬱鏇) = 範選鹽餘獵襯構築鬱齋 齋廠顧壓鏇壓壓齋網顧 (獵窪繭獵遞選壓鹽襯遞 ) | ||||||
N/A | 35 | (High Dose Alfacalcidol) | 壓鬱窪選餘鑰淵鏇鏇醖(衊願鏇鏇範膚顧簾觸築) = 繭範夢壓齋觸憲艱鹹獵 繭範淵範顧壓選衊簾網 (鑰鹹艱簾願顧蓋簾廠遞, 願獵憲醖鹽醖製衊鏇艱 ~ 蓋願構鑰獵鹹餘蓋鏇選) 更多 | - | 2016-01-25 | ||
(Low Dose Alfacalcidol) | 壓鬱窪選餘鑰淵鏇鏇醖(衊願鏇鏇範膚顧簾觸築) = 襯齋鹽鹹廠願齋醖鑰鏇 繭範淵範顧壓選衊簾網 (鑰鹹艱簾願顧蓋簾廠遞, 簾簾夢繭觸築構夢築繭 ~ 製簾膚遞鹹鏇遞膚窪願) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用